No Data
No Data
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Entrada Therapeutics: A Strong Buy on Robust Financials and Promising DMD Therapeutic Pipeline
Entrada Therapeutics (TRDA.US): The 2024 Q1 financial report achieved revenue of $59.12 million, previous value of USD 25.26 million, expected value of USD 14.98 million; earnings per share was USD 0.68, previous value was -0.21 USD, and expected value wa
Entrada Therapeutics (TRDA.US): The 2024 Q1 financial report achieved revenue of $59.12 million, previous value of USD 25.26 million, expected value of USD 14.98 million; earnings per share was USD 0.68, previous value was -0.21 USD, and expected value was -0.59 USD.
Entrada Therapeutics Q1 2024 GAAP EPS $0.68 May Not Be Comparable To $(0.52) Estimate, Sales $59.120M May Not Be Comparable To $14.977M Estimate
Entrada Therapeutics Q1 2024 GAAP EPS $0.68 May Not Be Comparable To $(0.52) Estimate, Sales $59.120M May Not Be Comparable To $14.977M Estimate
Entrada Therapeutics | 10-Q: Quarterly report
Entrada Therapeutics 1Q EPS 68c >TRDA
Entrada Therapeutics 1Q EPS 68c >TRDA
No Data